Fig. 5: Ref-1 promoted the maintenance of mutant BRAF function. | Cell Death & Disease

Fig. 5: Ref-1 promoted the maintenance of mutant BRAF function.

From: Pharmacological inhibition of Ref-1 enhances the therapeutic sensitivity of papillary thyroid carcinoma to vemurafenib

Fig. 5

A, B Western blot detection of MAPK pathway activation in DMSO, vemurafenib (10 μM), E3330 (50 μM), and combination (10 μM vemurafenib + 50 μM E3330) groups. C The mode of action of Ref-1 and BRAF determination by a Co-IP assay using TPC-1 cells with a BRAFV600E Tet-on system. D MAPK pathway activation detection by western blot assay after small interfering RNA targeting of Ref-1 with vemurafenib treatment.

Back to article page